KR100864743B1 - 비스포스포네이트의 투여 방법 - Google Patents

비스포스포네이트의 투여 방법 Download PDF

Info

Publication number
KR100864743B1
KR100864743B1 KR1020027017283A KR20027017283A KR100864743B1 KR 100864743 B1 KR100864743 B1 KR 100864743B1 KR 1020027017283 A KR1020027017283 A KR 1020027017283A KR 20027017283 A KR20027017283 A KR 20027017283A KR 100864743 B1 KR100864743 B1 KR 100864743B1
Authority
KR
South Korea
Prior art keywords
treatment
prevention
bisphosphonate
osteoporosis
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027017283A
Other languages
English (en)
Korean (ko)
Other versions
KR20030015283A (ko
Inventor
체불룬 디. 호로비쯔
피터 씨. 리차드슨
울리히 트레치셀
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100864743(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20030015283A publication Critical patent/KR20030015283A/ko
Application granted granted Critical
Publication of KR100864743B1 publication Critical patent/KR100864743B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027017283A 2000-06-20 2001-06-18 비스포스포네이트의 투여 방법 Expired - Lifetime KR100864743B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US09/597,135 2000-06-20
US26768901P 2001-02-09 2001-02-09
US60/267,689 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (2)

Publication Number Publication Date
KR20030015283A KR20030015283A (ko) 2003-02-20
KR100864743B1 true KR100864743B1 (ko) 2008-10-22

Family

ID=26952565

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017283A Expired - Lifetime KR100864743B1 (ko) 2000-06-20 2001-06-18 비스포스포네이트의 투여 방법

Country Status (24)

Country Link
US (1) US8052987B2 (enExample)
EP (1) EP1296689B3 (enExample)
JP (2) JP4722375B2 (enExample)
KR (1) KR100864743B1 (enExample)
CN (1) CN1272013C (enExample)
AT (1) ATE304856T1 (enExample)
AU (2) AU7410901A (enExample)
BR (1) BR0111806A (enExample)
CA (1) CA2410201C (enExample)
CY (2) CY1113740T1 (enExample)
CZ (1) CZ301972B6 (enExample)
DE (1) DE60113537T3 (enExample)
DK (1) DK1296689T3 (enExample)
ES (2) ES2247123T7 (enExample)
HU (1) HU228400B1 (enExample)
IL (2) IL153229A0 (enExample)
MX (1) MXPA02012682A (enExample)
NO (1) NO330459B1 (enExample)
NZ (1) NZ523086A (enExample)
PL (1) PL203087B1 (enExample)
PT (1) PT1591122E (enExample)
SK (1) SK287278B6 (enExample)
TW (1) TWI289451B (enExample)
WO (1) WO2001097788A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190685A1 (ko) * 2017-04-14 2018-10-18 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
KR20190007082A (ko) * 2019-01-14 2019-01-21 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ES2247123T7 (es) 2000-06-20 2013-03-01 Novartis Ag Método para administrar bisfosfonatos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
PT1880744E (pt) * 2002-05-10 2015-02-13 Hoffmann La Roche Ácidos bisfosfónicos para o tratamento e a prevenção da osteoporose
CA2497353C (en) * 2002-09-16 2012-08-28 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
WO2004035061A1 (en) * 2002-10-15 2004-04-29 Novartis Ag Method of administering bisphosphonates
PL212072B1 (pl) 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
CA2554749A1 (en) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x receptor inhibitor
ATE520406T1 (de) * 2004-08-23 2011-09-15 Teva Pharma Kristalline form des ibandronat-natriums
CN101087606B (zh) * 2004-12-09 2010-12-29 默沙东公司 雌激素受体调节剂
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20090075941A1 (en) * 2006-04-21 2009-03-19 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
WO2009137080A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PL2459176T3 (pl) 2009-07-31 2018-02-28 Grünenthal GmbH Sposób krystalizacji i biodostępność
HRP20150496T1 (hr) 2009-09-01 2015-08-14 Duke University, Office Of Licensing And Ventures Bisfosfonatne kompozicije i postupci tretiranja zatajenja srca
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE66608T1 (de) 1984-04-30 1991-09-15 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ATE72816T1 (de) * 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
BR9206941A (pt) 1991-12-17 1995-05-02 Procter & Gamble Pharma Métodos para o tratamento da osteoporose usando-se bifosfonatos e hormônio paratireóideo
DE69316013T2 (de) 1992-06-30 1998-07-09 Procter & Gamble Pharma Verwendung von phosphinate zur behandlung der osteoporose
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
KR970705399A (ko) 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골다공증용 포스포네이트 및 부갑상성 호르몬(phosphonates and parathyroid hormone for osteoporosis)
EP0779812A4 (en) 1994-09-09 1997-09-10 Procter & Gamble METHOD FOR TREATING OSTEOPOROSIS USING BONE-ACTIVE PHOSPHONATES AND PARATHORMONE
ATE290871T1 (de) 1995-09-29 2005-04-15 Novartis Pharma Gmbh Verfahren zur behandlung navikularer krankheiten bei pferden
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
EP1151752A3 (en) 1997-07-22 2002-12-18 MERCK & CO. INC. Method for inhibiting bone resorption
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
US20010044427A1 (en) * 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
ES2247123T7 (es) 2000-06-20 2013-03-01 Novartis Ag Método para administrar bisfosfonatos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190685A1 (ko) * 2017-04-14 2018-10-18 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
US11554129B2 (en) 2017-04-14 2023-01-17 Industry-Academic Cooperation Foundation, Yonsei University Composition for treating chronic renal transplant dysfunction comprising bisphosphonate
KR20190007082A (ko) * 2019-01-14 2019-01-21 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
KR102049233B1 (ko) 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
DE60113537T3 (de) 2013-05-29
CY1113740T1 (el) 2015-08-05
JP4722375B2 (ja) 2011-07-13
WO2001097788A3 (en) 2002-06-27
CA2410201C (en) 2010-10-26
NO330459B1 (no) 2011-04-18
DK1296689T3 (da) 2005-11-28
BR0111806A (pt) 2003-05-20
ES2247123T7 (es) 2013-03-01
EP1296689A2 (en) 2003-04-02
CA2410201A1 (en) 2001-12-27
WO2001097788A2 (en) 2001-12-27
TWI289451B (en) 2007-11-11
CZ20024134A3 (cs) 2003-06-18
US20030181421A1 (en) 2003-09-25
PL358224A1 (en) 2004-08-09
CY2013011I1 (el) 2015-08-05
DE60113537D1 (de) 2006-02-02
HUP0301164A2 (hu) 2003-08-28
AU7410901A (en) 2002-01-02
NZ523086A (en) 2007-07-27
KR20030015283A (ko) 2003-02-20
HU228400B1 (en) 2013-03-28
HK1072539A1 (en) 2005-09-02
IL153229A (en) 2007-07-24
EP1296689B3 (en) 2013-02-13
ATE304856T1 (de) 2005-10-15
ES2394211T3 (es) 2013-01-23
PL203087B1 (pl) 2009-08-31
EP1296689B1 (en) 2005-09-21
US8052987B2 (en) 2011-11-08
SK287278B6 (sk) 2010-05-07
ES2247123T3 (es) 2006-03-01
NO20026117D0 (no) 2002-12-19
JP2003535889A (ja) 2003-12-02
NO20026117L (no) 2002-12-19
CN1620300A (zh) 2005-05-25
CN1272013C (zh) 2006-08-30
IL153229A0 (en) 2003-07-06
MXPA02012682A (es) 2003-04-25
CY2013011I2 (el) 2015-08-05
PT1591122E (pt) 2012-12-12
AU2001274109B2 (en) 2004-12-23
DE60113537T2 (de) 2006-06-29
JP5005188B2 (ja) 2012-08-22
CZ301972B6 (cs) 2010-08-18
JP2005247873A (ja) 2005-09-15
HUP0301164A3 (en) 2005-11-28
SK18082002A3 (sk) 2003-08-05

Similar Documents

Publication Publication Date Title
KR100864743B1 (ko) 비스포스포네이트의 투여 방법
US20070161603A1 (en) Method of administering bisphosphonates
KR100866025B1 (ko) 통증 치료를 위한 비스포스포네이트의 용도
AU2001274109A1 (en) Method of administering bisphosphonates
RU2297229C2 (ru) Фармацевтическое применение бисфосфонатов
JPH09512816A (ja) プロテーゼのゆるみ及びプロテーゼの移動を防止するための特定メタンビスホスホン酸誘導体の使用
RU2288722C2 (ru) Способ введения бисфосфонатов
HK1072539B (en) Use of bisphosphonates in the preparation of a medicment for the treatment of conditings of abnormally increased bone turnover

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060619

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070509

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071015

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080522

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071015

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070509

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080620

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080522

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080722

Appeal identifier: 2008101005803

Request date: 20080620

AMND Amendment
E701 Decision to grant or registration of patent right
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080630

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080620

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080215

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070709

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060619

Patent event code: PB09011R02I

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20080722

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20081015

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20081015

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110921

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20120924

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130926

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130926

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140923

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150918

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160921

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20211218

Termination category: Expiration of duration